NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Stock Information for NeuroSense Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.